HemoSonics LLC
$336.6K 219 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. reported $337,131.84 across General Payments, Research, and Ownership to 658 physicians and teaching hospitals across 658 transactions.
- $337.1K Above-median payer
- All-tracks total
- 658 Above-median volume
- Transactions
- 658 Above-median reach
- Recipients
- +$159.8K
- General Payments vs PY2023
Noven Pharmaceuticals, Inc. reported $337,131.84 across all CMS Open Payments tracks (General + Research + Ownership) to 658 physicians and teaching hospitals in Program Year 2024 - ranking #866 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $337,131.84, averaging $512.36 per recipient.
Noven Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
23/100
Total payments
F
13/100
Transaction volume
F
15/100
Physician reach
F
15/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer noven-pharmaceuticals-inc Noven Pharmaceuticals, Inc.
$337.1K · #866/1,925 · 0.0% industry · PY2024
- TOT $337.1K
- RANK #866
- SHARE 0.0%
- TXN 658
- RCP 658
- CAT 4
- GEN $337.1K
- ΔGEN +$159.8K
- TOP1 11.9%
- PY 2024
Volume peers
Nearest volume peer: HemoSonics LLC ($336.6K)
Noven Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Noven Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $159.8K (+90.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOVEN PHARMACEUTICALS, INC.PY2023: NOVEN PHARMACEUTICALS, INC.PY2024: Noven Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $177,368.68
- PY2024
- $337,131.84
What the Data Shows for Noven Pharmaceuticals, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Noven Pharmaceuticals, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Faculty or Speaker (Medical Education)" at $266.9K, accounting for 79.2% of this company's General Payments and 151 transactions.
General Payment Breakdown by Type
Across 4 types of general payments, Noven Pharmaceuticals, Inc.'s largest category was "Compensation for Faculty or Speaker (Medical Education)" at $266.9K - 79.2% of General Payments.
Noven Pharmaceuticals, Inc. reports 4 general-payment categories - the top three are Compensation for Faculty or Speaker (Medical Education) (79.2%), Food and Beverage (9.4%), and Travel and Lodging (7.3%). The remaining 1 category make up 4.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Noven Pharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Faculty or Speaker (Medical Education) | $266.9K | 151 | 79.2% |
| Food and Beverage | $31.6K | 432 | 9.4% |
| Travel and Lodging | $24.7K | 65 | 7.3% |
| Consulting Fee | $13.9K | 10 | 4.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $128,599.54 (38.1%) of $337,131.84 in this company's General Payments records across 401 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Noven Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Michelle Holloway
$39,975.57 across 37 reported transactions
- 2
Birgit Amann
$29,277.92 across 24 reported transactions
- 3
Gregory Mattingley
$21,678.13 across 16 reported transactions
- 4
Napoleon Higgins
$20,020.37 across 19 reported transactions
- 5
Andrew Cutler
$17,647.55 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Noven Pharmaceuticals, Inc. ranks #866 of 1,925 by total payments (top 45% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,308 of 1,838 by HHI (bottom 29% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Octapharma USA, Inc. : $1.0M total payments, HHI 480
- Alliance Medical : $6.2K total payments, HHI 480
- Kyocera Medical Technologies, Inc. : $689.6K total payments, HHI 480
- GC America Inc. : $524.2K total payments, HHI 479
- Align Technology, Inc. : $16.8M total payments, HHI 478
- Canon Medical Systems USA, Inc. : $437.4K total payments, HHI 477
- Noven Pharmaceuticals, Inc. (this company) : $337.1K total payments, HHI 473
- Shoulder Innovations, Inc. : $2.2M total payments, HHI 471
- Sage Therapeutics, Inc. : $815.5K total payments, HHI 470
- IsoRay, Inc : $2.5K total payments, HHI 469
- International Rehabilitative Sciences, Inc : $502.5K total payments, HHI 469
- ZOLL Circulation Inc : $600.9K total payments, HHI 468
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Noven Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Noven Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Noven Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
UCB Biosciences Inc.
$337.8K 13 recipients
Compare payment profiles
Intuitive Surgical Operations, Inc.
$335.6K 0 recipients
Compare payment profiles
ALK-Abello, Inc
$339.4K 4,525 recipients
Compare payment profiles
Phadia US Inc.
$339.5K 6,871 recipients
Compare payment profiles
Carl Zeiss Meditec AG
$341.0K 11 recipients
Compare payment profiles
Put this to use
Noven Pharmaceuticals, Inc. ranks #866 of 1,925 by all-tracks total payments, led by "Compensation for Faculty or Speaker (Medical Education)".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Faculty or Speaker (Medical Education)" spend across every manufacturer, not just Noven Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.